PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ

Reported: January 15, 2025 Initiated: December 30, 2024 #D-0190-2025

Product Description

Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ

Reason for Recall

CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Details

Units Affected
244,460 bottles
Distribution
Nationwide
Location
East Brunswick, NJ

Frequently Asked Questions

What product was recalled?
Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30) and b) 1000 count (NDC 57237-019-99) bottles; Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ. Recalled by Rising Pharma Holding, Inc.. Units affected: 244,460 bottles.
Why was this product recalled?
CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 15, 2025. Severity: Moderate. Recall number: D-0190-2025.